Insulin Resistance in Smokers Undergoing Smoking Cessation

Charles Drew University of Medicine and Science

Status

Terminated

Conditions

Insulin Resistance

Cardiovascular Disease

Treatments

Behavioral: Smoking cessation

Study type

Interventional

Funder types

Other

Identifiers

NCT00877513

08-02-2165

Details and patient eligibility

About

Cigarette smoking increases CVD risk and worsens insulin resistance, but also contributes to weight loss; smoking cessation reduces CVD risk and improves insulin sensitivity, but also contributes to weight gain. The mechanisms that underlie these metabolic changes of cigarette smoking and smoking cessation on insulin resistance, body composition, and fat distribution are poorly understood.

Full description

This study is a prospective, open cohort study of smokers who undergo a smoking cessation program, and who subsequently may or may not resume smoking spontaneously. Eligible subjects will be characterized at baseline with respect to their metabolic and CVD risk profiles, body fat composition and distribution. Subjects will then undergo an intensive 8-week smoking cessation program using bupropion plus cognitive behavioral counseling. Those who successfully abstain will be reassessed. Since most individuals who quit smoking will naturally resume smoking again over time, subjects will be assessed again after an additional 4 months of follow-up when a subset of subjects will be expected to have naturally resumed smoking.

Enrollment

103 patients

Sex

All

Ages

25 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 25 to 70 inclusive; any ethnicity
Cigarette smoking for at least 3 years, at a rate of at least 1 but not more than 2 packs per day
BMI 19 kg/m2 or greater and 40 kg/m2 or less
Willing to enter, and be able to comply with the instructions and scheduled follow-up of a smoking cessation program

Exclusion criteria

Any physical disabilities that prevent the subject from participating in the study, as determined by the investigators
History of CVD (ventricular arrhythmias, atrial arrhythmias with a history of hemodynamic instability, unstable angina, myocardial infarction, invasive coronary revascularization, or any hospitalization for CVD within the last 3 years, NYHA Class III or IV CHF)
Current abuse of illicit drugs or heavy ethanol use
History or baseline laboratory evidence of diabetes mellitus
History of chronic obstructive pulmonary disease (COPD)
BMI < 19 or > 40 kg/m2
Subjects not following a regular diet and lifestyle pattern (e.g, homeless)
Uncontrolled hypertension (BP 170 mmHg or greater systolic or 110 mmHg or greater diastolic)
Fasting triglycerides 700 mg/dL or greater, or LDL-cholesterol 200 mg/dL or greater
History of chronic renal or liver disease (hepatic transaminase elevations > 3 times the upper limit of the normal range; creatinine > 1.5 mg/L), malignancies not currently in remission, gastrointestinal disorders that interfere with nutrition; history of malnutrition, chronic infections (including HIV), or recent (within 30 days) surgeries or hospitalizations
Concurrent use of medications that may alter metabolic parameters (including metformin, sulfonylurea agents, thiazolidinediones, weight loss agents, androgens or systemic glucocorticoids); lipid-lowering agents and oral contraceptives will be permitted as long as formulations, dosages and adherence remain unchanged throughout the course of the study. Oral contraceptives that are started during the course of the study will require the subject to be withdrawn from the study
Perimenopausal women experiencing irregular menses, because of changing metabolic status during the perimenopause; these patients may be included if menses have ceased for at least 6 months
Women who are pregnant, seeking to become pregnant in the next 6 months, or who are breastfeeding
Any history of depression, suicidality, or any contraindications to bupropion (history of seizures, anorexia or bulimia)
Current use of nicotine replacement products (gum or patch)
Any other factors that, in the opinion of the investigators, may interfere with the safe conduct, successful completion, or data integrity of the study